Literature DB >> 26702135

Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity.

Phillipp Hartmann1, Caroline T Seebauer1, Magdalena Mazagova1, Angela Horvath1, Lirui Wang2, Cristina Llorente2, Nissi M Varki3, Katharina Brandl4, Samuel B Ho2, Bernd Schnabl5.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and obesity are characterized by altered gut microbiota, inflammation, and gut barrier dysfunction. Here, we investigated the role of mucin-2 (Muc2) as the major component of the intestinal mucus layer in the development of fatty liver disease and obesity. We studied experimental fatty liver disease and obesity induced by feeding wild-type and Muc2-knockout mice a high-fat diet (HFD) for 16 wk. Muc2 deficiency protected mice from HFD-induced fatty liver disease and obesity. Compared with wild-type mice, after a 16-wk HFD, Muc2-knockout mice exhibited better glucose homeostasis, reduced inflammation, and upregulated expression of genes involved in lipolysis and fatty acid β-oxidation in white adipose tissue. Compared with wild-type mice that were fed the HFD as well, Muc2-knockout mice also displayed higher intestinal and plasma levels of IL-22 and higher intestinal levels of the IL-22 target genes Reg3b and Reg3g. Our findings indicate that absence of the intestinal mucus layer activates the mucosal immune system. Higher IL-22 levels protect mice from diet-induced features of the metabolic syndrome.

Entities:  

Keywords:  Reg3; endotoxin; metabolic syndrome; microbiome

Mesh:

Substances:

Year:  2015        PMID: 26702135      PMCID: PMC4773827          DOI: 10.1152/ajpgi.00094.2015

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  48 in total

1.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

2.  Evaluation of universal probes and primer sets for assessing total bacterial load in clinical samples: general implications and practical use in endodontic antimicrobial therapy.

Authors:  H P Horz; M E Vianna; B P F A Gomes; G Conrads
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Colorectal cancer in mice genetically deficient in the mucin Muc2.

Authors:  Anna Velcich; WanCai Yang; Joerg Heyer; Alessandra Fragale; Courtney Nicholas; Stephanie Viani; Raju Kucherlapati; Martin Lipkin; Kan Yang; Leonard Augenlicht
Journal:  Science       Date:  2002-03-01       Impact factor: 47.728

4.  Ketone body kinetics in humans: the effects of insulin-dependent diabetes, obesity, and starvation.

Authors:  S E Hall; M E Wastney; T M Bolton; J T Braaten; M Berman
Journal:  J Lipid Res       Date:  1984-11       Impact factor: 5.922

Review 5.  Obesity and cancer.

Authors:  Tobias Pischon; Ute Nöthlings; Heiner Boeing
Journal:  Proc Nutr Soc       Date:  2008-05       Impact factor: 6.297

6.  Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation.

Authors:  Svetlana Radaeva; Rui Sun; Hong-Na Pan; Feng Hong; Bin Gao
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

7.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

Authors:  G S Hotamisligil; P Arner; J F Caro; R L Atkinson; B M Spiegelman
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly.

Authors:  M Carmen Collado; Muriel Derrien; Erika Isolauri; Willem M de Vos; Seppo Salminen
Journal:  Appl Environ Microbiol       Date:  2007-10-12       Impact factor: 4.792

10.  Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR.

Authors:  T Rinttilä; A Kassinen; E Malinen; L Krogius; A Palva
Journal:  J Appl Microbiol       Date:  2004       Impact factor: 3.772

View more
  18 in total

Review 1.  Gut-liver axis at the frontier of host-microbial interactions.

Authors:  Katharina Brandl; Vipin Kumar; Lars Eckmann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-02-23       Impact factor: 4.052

Review 2.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

3.  Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22.

Authors:  Qinglan Wang; So Yeon Kim; Hiroshi Matsushita; Zhijun Wang; Vijay Pandyarajan; Michitaka Matsuda; Koichiro Ohashi; Takashi Tsuchiya; Yoon Seok Roh; Calvin Kiani; Yutong Zhao; Michael Chan; Suzanne Devkota; Shelly C Lu; Tomoko Hayashi; Dennis A Carson; Ekihiro Seki
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-21       Impact factor: 11.205

4.  Fenretinide Reduces Intestinal Mucin-2-Positive Goblet Cells in Chronic Alcohol Abuse.

Authors:  Marta Melis; Xiao-Han Tang; Karen Mai; Lorraine J Gudas; Steven E Trasino
Journal:  Pharmacology       Date:  2022-05-12       Impact factor: 3.429

Review 5.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

6.  Dietary capsaicin and antibiotics act synergistically to reduce non-alcoholic fatty liver disease induced by high fat diet in mice.

Authors:  Jingjuan Hu; Haihua Luo; Yong Jiang; Peng Chen
Journal:  Oncotarget       Date:  2017-06-13

Review 7.  Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites.

Authors:  Andrea Verdugo-Meza; Jiayu Ye; Hansika Dadlani; Sanjoy Ghosh; Deanna L Gibson
Journal:  Nutrients       Date:  2020-05-15       Impact factor: 5.717

8.  The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis.

Authors:  Sena Bluemel; Lirui Wang; Cameron Martino; Suhan Lee; Yanhan Wang; Brandon Williams; Angela Horvath; Vanessa Stadlbauer; Karsten Zengler; Bernd Schnabl
Journal:  Hepatol Commun       Date:  2018-02-28

Review 9.  The Interleukin-20 Cytokine Family in Liver Disease.

Authors:  Esther Caparrós; Rubén Francés
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

10.  Dietary fibers inhibit obesity in mice, but host responses in the cecum and liver appear unrelated to fiber-specific changes in cecal bacterial taxonomic composition.

Authors:  Janice E Drew; Nicole Reichardt; Lynda M Williams; Claus-Dieter Mayer; Alan W Walker; Andrew J Farquharson; Stavroula Kastora; Freda Farquharson; Graeme Milligan; Douglas J Morrison; Tom Preston; Harry J Flint; Petra Louis
Journal:  Sci Rep       Date:  2018-10-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.